We are live on ! Find out more
MDCO

Medicines Co
MDCO

Delisted

MDCO was delisted on the 3rd of January, 2020.

228 hedge funds and large institutions have $3.76B invested in Medicines Co in 2019 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 91 increasing their positions, 57 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 25

60% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 57

34% more capital invested

Capital invested by funds: $2.8B → $3.76B (+$958M)

33% more funds holding in top 10

Funds holding in top 10: 68 (+2)

12% more funds holding

Funds holding: 203228 (+25)

30% less call options, than puts

Call options by funds: $224M | Put options by funds: $320M

Holders
228
Holders Change
+25
Holders Change %
+12.32%
% of All Funds
4.95%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.17%
New
52
Increased
91
Reduced
57
Closed
25
Calls
$224M
Puts
$320M
Net Calls
-$95.3M
Net Calls Change
-$70.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$400M +$21.8M +667,776 +6%
BlackRock
2
BlackRock
New York
$399M +$11.5M +352,320 +3%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$396M -$3.87M -118,405 -1%
Vanguard Group
4
Vanguard Group
Pennsylvania
$271M +$15M +460,064 +7%
Westfield Capital Management
5
Westfield Capital Management
Massachusetts
$169M -$21M -643,473 -12%
SCM
6
Sarissa Capital Management
Connecticut
$153M +$18.5M +566,000 +16%
MC
7
Maverick Capital
Texas
$141M +$1.72M +52,731 +1%
State Street
8
State Street
Massachusetts
$133M +$46.7M +1,431,349 +65%
SPC
9
Slate Path Capital
New York
$129M +$44.9M +1,375,000 +63%
IAM
10
Iridian Asset Management
Connecticut
$126M -$11.9M -363,525 -10%
BM
11
Bridger Management
New York
$84.4M -$17.2M -527,747 -19%
PI
12
Putnam Investments
Massachusetts
$64.3M +$3.48M +106,535 +6%
Bank of America
13
Bank of America
North Carolina
$63.7M -$19.7M -604,662 -26%
CCM
14
Camber Capital Management
Massachusetts
$62M -$25.2M -771,523 -31%
Macquarie Group
15
Macquarie Group
Australia
$46.1M -$14.6M -445,964 -26%
AG
16
Artal Group
Luxembourg
$36.5M +$9.79M +300,000 +43%
AH
17
Aviva Holdings
Bahamas
$35.8M -$91.3M -2,795,911 -74%
ACA
18
Avoro Capital Advisors
New York
$33.7M -$20.8M -637,000 -41%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$33.1M +$2.35M +72,103 +9%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$31.9M +$3.06M +93,781 +12%
Northern Trust
21
Northern Trust
Illinois
$31.8M +$352K +10,796 +1%
Goldman Sachs
22
Goldman Sachs
New York
$31.1M +$4.94M +151,224 +22%
RSCM
23
Rock Springs Capital Management
Maryland
$29.2M +$2.3M +70,600 +10%
Ameriprise
24
Ameriprise
Minnesota
$28.6M +$691K +21,164 +3%
BC
25
Boxer Capital
California
$27.4M +$4.9M +150,000 +25%

MDCO Hedge Fund Activity: Q2 2019 in Review

228 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q2 2019, worth a combined $3.76B — up 34% from $2.8B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new MDCO positions and 25 closed out — a net gain of 27 holders — while 91 added to existing stakes and 57 trimmed.

The largest buyer was State Street, adding an estimated $46.7M. The largest seller was Aviva Holdings, cutting an estimated $91.3M.

  • 228 institutional investors held Medicines Co (MDCO) as of Q2 2019, up from 203 in Q1 2019.
  • Funds reported $3.76B of Medicines Co stock for Q2 2019, up 34% quarter-over-quarter.
  • 52 funds opened new Medicines Co positions in Q2 2019 and 25 closed out, a net change of +27 holders.
  • The largest Medicines Co buyer in Q2 2019 was State Street, an estimated $46.7M added.
  • The largest Medicines Co seller in Q2 2019 was Aviva Holdings, an estimated $91.3M sold.

Based on aggregated 13F filings for Q2 2019.